Treatment(s) now being considered-Biological therapy Posts on Medivizor
Navigation Menu

Treatment(s) now being considered-Biological therapy Posts on Medivizor

Which scanning method is more accurate for patients with relapsed or refractory Hodgkin lymphoma who received biological therapy?

Posted by on May 9, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared CT and PET scans to understand which was more accurate at predicting biological treatment results in patients with relapsed or refractory Hodgkin lymphoma (HL). The results showed that PET scans were more sensitive than CT scans in these patients. Some background Biological therapy has improved treatment results...

Read More

Long-term outcomes of pertuzumab added to trastuzumab and docetaxel treatment for patients with advanced HER2-positive breast cancer

Posted by on Apr 7, 2020 in Breast cancer | 0 comments

In a nutshell This study looked at whether pertuzumab (Perjeta) benefits patients with metastatic HER2-positive breast cancer when added to trastuzumab (Herceptin) and docetaxel (Taxotere) treatment. They found that adding pertuzumab improved long-term patient outcomes. Some background Breast cancer can now be tested for some of the signals involved...

Read More

Do biological drugs work better alone or in combination with other drugs for patients with advanced non-small cell lung cancer who previously received treatment?

Posted by on Apr 7, 2020 in Lung cancer | 0 comments

In a nutshell This study compared if anti-PD-1 biological drugs were more effective alone or when used with other drugs to treat patients with advanced non-small cell lung cancer who had previously received treatment. The results showed that the combination of anti-PD-1 and other drugs such as chemotherapy improved patients’ survival more than...

Read More

How effective is long-term brentuximab vedotin treatment for patients with recurrent or non-responding Hodgkin’s lymphoma?

Posted by on Jan 12, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated long-term treatment with brentuximab vedotin (Adcetris) for patients with Hodgkin's lymphoma (HL) that has come back or stopped responding to treatment. This study concluded that this treatment had a long-term benefit for some patients. Some background Most patients with HL respond well to initial treatment....

Read More

Early 18F-FDG PET/CT response can predict survival in patients with Hodgkin lymphoma treated with nivolumab

Posted by on Nov 17, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate if 18F-FDG PET/CT (ePET1) imaging can predict overall survival in patients with relapsed or unresponsive (refractory) Hodgkin lymphoma who have been treated with nivolumab.   This study concluded that ePET1 assessment can predict overall survival in these patients.  Some...

Read More

Epidermal growth factor ointment improves the treatment of skin side effects in patients receiving treatment for colorectal cancer

Posted by on Sep 26, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of epidermal growth factor (EGF) ointment to treat skin side effects in patients with colorectal cancer receiving epidermal growth factor receptor (EGFR) inhibitor treatment. Researchers suggested that EGF ointment improves the outcomes and quality of life of these patients. Some background...

Read More

Side effects of ado-trastuzumab emtansine impacting outcomes in patients with HER2+ advanced breast cancer

Posted by on Aug 25, 2019 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the impact of early side effects requiring ado-trastuzumab emtansine dose interruptions or reductions on outcomes for patients with HER2+ advanced metastatic breast cancer.  This study concluded that these side effects do not impact the outcomes for these patients.   Some background...

Read More

Cetuximab improves the outcomes of previously untreated patients with metastatic colorectal cancer

Posted by on May 28, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of first-line treatment with cetuximab (Erbitux) and bevacizumab (Avastin) in advanced colorectal cancer. Researchers suggested that cetuximab is associated with better outcomes when compared to bevacizumab.    Some background Colorectal cancer is the third most common cancer worldwide....

Read More